Dimenhydrinate Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg, 100 mg
Reference Brands: Dramamine(US & EU)
Category:
Antiemetic
Dimenhydrinate is an antihistamine that blocks H1 receptors in the brain and inner ear, reducing nausea, vertigo, and motion sickness. It quickly alleviates symptoms, supports balance, and prevents vomiting during travel or inner ear disorders. Benefits include symptom relief, improved stability, and enhanced comfort in nausea management.
Dimenhydrinate tablets is available in Tablets
and strengths such as 50 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dimenhydrinate tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dimenhydrinate tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dimenhydrinate tablets, marketed as Dramamine and generics, are approved in the US by the FDA and in the EU via EMA for preventing motion sickness, nausea, and vertigo. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for various indications, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports timely approval, safe use, and worldwide availability of dimenhydrinate tablets, helping manage motion sickness and nausea effectively across healthcare regions globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing